Portal de Periódicos da CAPES

Controlled Release Levodopa/Carbidopa 25/100 (Sinemet CR 25/100)

1994; Lippincott Williams & Wilkins; Volume: 17; Issue: 5 Linguagem: Inglês

10.1097/00002826-199410000-00005

1537-162X

John P. Hammerstad, William R. Woodward, John G. Nutt, Stephen T. Gancher, Gilbert Block, GEORGE M. CYHAN,

Epilepsy research and treatment

Summary The pharmacokinetics of the clinically determined optimal dose of controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100) after 12 weeks of therapy was studied in nine parkinsonian patients without prior exposure to levodopa. The pharmacokinetics of single oral doses of controlled release levodopa/carbidopa 25/100 and 50/200 were also compared. As predicted from the plasma half-life (1.7 ± 0.3 h) and confirmed by morning trough levels, levodopa did not accumulate when controlled released levodopa/carbidopa 25/100 was administered twice daily. The absorption and bioavailability of CR 25/100 are minimally greater than CR 50/200. Controlled released levodopa/carbidopa 25/100 levodopa plasma levels peak slightly faster than controlled release levodopa/carbidopa 50/200.